Latest profit margin for Celyad Oncology S.A.: -1650.26% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
As of the most recent data (June 2026), CLYYF shows a profit margin of -1650.26%. That compares with 5892.24% in the prior-year period — down 128.0% year over year. That is below the Healthcare sector average of 9.48%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CLYYF's profit margin is now -1650.26% (was 5892.24%) — a 128.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Celyad Oncology S.A. is outperforming or lagging.
The Healthcare sector average profit margin is about 9.48%. Celyad Oncology S.A. is at -1650.26%, which is lower that average. That is roughly 17506.0% below the sector mean. Use the comparison chart on this page to see how CLYYF stacks up against individual peers as well.
That compares with 5892.24% in the prior-year period — down 128.0% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Celyad Oncology S.A. with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Celyad Oncology S.A.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -1650.26%) with ownership activity and broader fundamentals.